Major depressive disorder: mechanism-based prescribing for personalized medicine
Philip F Saltiel,1 Daniel I Silvershein2 1Department of Psychiatry, New York University School of Medicine/Langone Medical Center New York University Behavioral Health Programs, New York University Pearl Barlow Center for Memory Evaluation and Treatment, New York, NY, USA; 2Department of Medicine,...
Saved in:
Main Authors: | Saltiel PF, Silvershein DI |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/29eb824b2afb4da09a4d53c473f72fcb |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Desvenlafaxine in the treatment of major depressive disorder
by: Maria Teresa C Lourenco1, et al.
Published: (2009) -
Psychiatric comorbidities in patients with major depressive disorder
by: Thaipisuttikul P, et al.
Published: (2014) -
Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
by: Kawamura S, Maesawa C, Nakamura K, Nakayama K, Morita M, Hiruma Y, Yoshida T, Sakai A, Masuda T
Published: (2011) -
Comparative efficacy of escitalopram in the treatment of major depressive disorder
by: Mazen K Ali, et al.
Published: (2011) -
Augmentation treatment in major depressive disorder: focus on aripiprazole
by: J Craig Nelson, et al.
Published: (2008)